Advances in Cancer Vaccines: Will Regulators Keep Pace?

November 19, 2026

In the last few days, scientists disclosed results from two major clinical studies that could signal a new chapter in cancer care. Researchers are discovering how to train the immune system to battle cancer and, potentially, to avert certain cancers from arising in the first place. These findings also challenge the manner in which the Food and Drug Administration (FDA) assesses new medicines.

On November 17, Memorial Sloan Kettering Cancer Center announced that an experimental vaccine markedly extended survival in people with acute myeloid leukemia (AML), a lethal cancer of the blood and marrow. Six days earlier, The New England Journal of Medicine published the outcomes of a trial showing that a personalized messenger RNA (mRNA) vaccine lowered the odds that melanoma, a potentially deadly skin cancer, would return after surgery.

Traditional vaccines prime the immune system to identify and attack invading organisms, such as viruses and bacteria. Cancer vaccines pose a more intricate challenge: they must teach the immune system to distinguish cancerous cells from normal ones. Fortunately, cancer cells frequently produce abnormal proteins or unusually high levels of normal proteins that the immune system can learn to spot.

The leukemia vaccine galinpepimut-S contains laboratory-made peptides (short protein fragments) that imitate segments of a protein known as Wilms tumor 1 (WT1). More than 95 percent of AML patients have leukemia cells that express WT1. The vaccine trains the immune system’s cancer-fighting T cells to recognize and attack leukemia cells that may have survived chemotherapy.

In a trial involving 126 patients whose leukemia had returned after treatment and who later achieved a second remission, researchers found that those who received the vaccine lived a median of 24 months, compared with 14.7 months for those who got other available therapies. None of the patients in the study qualified for a bone marrow transplant. The vaccine’s developer has not yet released the full trial data.

The melanoma vaccine adopts a more individualized strategy, employing the same foundational mRNA technology used in COVID-19 vaccines.

Investigators examine a patient’s surgically removed tumor DNA to identify mutations that drive cancer cells to produce distinctive proteins. They then manufacture a vaccine containing genetic instructions that cause some of the patient’s healthy cells to temporarily produce fragments of those proteins. The immune system learns to recognize these molecular fingerprints and target any remaining cancer cells that display them.

The vaccine, named intismeran, was developed by Moderna and Merck and can target up to 34 molecular fingerprints unique to an individual patient’s tumor. The investigators combined the vaccine with pembrolizumab (Keytruda), a drug that helps prevent cancer cells from disabling the immune system’s attack.

In a trial with 1,137 melanoma patients who had undergone surgical procedures, 82.2 percent of those who received both the vaccine and pembrolizumab remained alive and cancer-free two years later, compared with 70 percent of those who received pembrolizumab alone.

Researchers at Johns Hopkins University are investigating whether vaccines might even stop pancreatic cancer from developing, one of the deadliest forms of the disease.

The KRAS (Kirsten rat sarcoma viral oncogene homolog) gene provides instructions for making a protein that acts like a molecular switch, guiding signals that tell cells when to grow and divide. Certain mutations can keep that switch permanently “on,” promoting unchecked cellular growth. Uncontrolled growth and the capacity of abnormal cells to invade nearby tissues are among the defining traits of cancer. More than 90 percent of pancreatic cancers harbor KRAS mutations, which can occur ten years or more before cancer emerges.

In July, Johns Hopkins researchers reported that an experimental peptide vaccine targeting six common KRAS mutations elicited a robust immune response in 18 of 20 individuals at high risk of developing pancreatic cancer. The vaccine contains lab-made fragments of the abnormal proteins produced by these mutations, teaching the immune system to recognize and attack cells carrying them. Researchers detected vaccine-induced immune cells for as long as two years. While the small study cannot demonstrate cancer prevention, it raises the alluring possibility of training the immune system to eliminate precancerous cells before they become malignant tumors.

These advances should cause lawmakers to pause before passing judgment on entire fields of medical technology. Last year, Health and Human Services Secretary Robert F. Kennedy Jr. announced that his department would wind down 22 investments in mRNA vaccine development targeting infectious diseases. Regardless of one’s view on taxpayer support for medical research, policymakers have limited ability to foresee where a technology may lead or which of its applications will prove most valuable.

Personalized medicine poses an even more fundamental test for federal regulators.

For most of the pharmaceutical industry’s history, manufacturers produced identical drug formulations for thousands or even millions of patients. Researchers test a given formulation in clinical trials, and the FDA evaluates the results before allowing its sale.

With personalized cancer vaccines, a company might manufacture a thousand distinct formulations for a thousand different patients.

Regulators must assess how reliably manufacturers identify the correct genetic mutations, design the genetic instructions, produce individual doses, and ensure that each patient receives the right vaccine. An October review in Frontiers in Immunology examined these and other hurdles that personalized mRNA therapies pose for regulatory agencies.

The FDA already has some experience with individualized treatments. It has approved several chimeric antigen receptor (CAR) T-cell therapies, in which manufacturers genetically modify a patient’s own immune cells to attack cancer. But as scientists devise more ways to tailor therapies to individuals, regulators will increasingly need to evaluate not only the clinical evidence that a medicine works but also the dependability of the processes that manufacture it.

Why assume that a single government agency can keep pace with these rapidly changing technologies more effectively than several independent bodies?

Competing certification organizations could concentrate on different branches of personalized medicine, create and refine evaluation methods as science advances, and provide physicians and patients with independent judgments about safety and efficacy. Competition would allow diverse evaluation approaches to emerge and improve as groups learn from one another’s triumphs and missteps. A regulatory monopoly, by contrast, traps everyone in the consequences of the same mistakes.

Congress should end the FDA’s monopoly over drug approval and empower patients and their doctors to decide whose scientific assessments they trust and how much uncertainty they are willing to tolerate.

As medical innovation accelerates, the FDA will find it increasingly hard to keep up. Cancer patients may lose precious time waiting for therapies that could have saved their lives.

Natalie Foster

I’m a political writer focused on making complex issues clear, accessible, and worth engaging with. From local dynamics to national debates, I aim to connect facts with context so readers can form their own informed views. I believe strong journalism should challenge, question, and open space for thoughtful discussion rather than amplify noise.